(EMAILWIRE.COM, September 27, 2019 ) The latest report by IMARC Group, titled “Oncology Biosimilars Market Research Report and Forecast 2019-2024”, finds that the global oncology biosimilars market size reached US$ 408 Million in 2018. Oncology biosimilars are cost-effective counterparts of the already licensed reference biologics. They are similar in terms of quality, safety and efficiency to their branded counterparts, and are widely being used in cancer treatment. Biological therapies are large, highly complex molecules derived from living cells or organisms. The extensive research involved in the development of originator drugs, coupled with aggressive marketing and promotion by the manufacturer, leads to high costs. Since biosimilars only require such studies to ensure equivalence of efficacy and safety profiles, they incur lower manufacturing costs, which in turn help in reducing treatment expenses.

Request for a free sample copy of this report: https://www.imarcgroup.com/oncology-biosimilars-market/requestsample

Global Oncology Biosimilars Market Trends:

According to the World Health Organization, cancer resulted in an estimated 9.6 million deaths in 2018, representing the second leading cause of death globally. The rising prevalence of cancer, along with the upcoming patent expiry of several blockbuster oncology drugs, has encouraged pharmaceutical manufacturers to develop biosimilars for use in oncology. Additionally, several regulatory authorities have also approved biosimilars to offer a safe and affordable alternative to originator biological therapies. These cost-effective biosimilars provide significant savings, better access to treatment, and the potential of improved outcomes. Moreover, several leading manufacturers are entering into partnerships to develop oncology drugs. For instance, Biocon, Asia’s premier biopharmaceutical company, has collaborated with Sandoz, a Novartis division and the global leader in biosimilars, to develop, manufacture and commercialize next-generation biosimilars for patients worldwide to help them gain access to a range of high-quality and affordable oncology biologics. According to the oncology biosimilars market report, the market value is projected to reach US$ 6,268 Million by 2024, expanding at a CAGR of 57.6% during 2019-2024.

Explore full report with table of contents: https://www.imarcgroup.com/oncology-biosimilars-market

Market Summary:

Market Breakup by Drug Type:

1. Monoclonal Antibody
2. Immunomodulators
3. G-CSF
4. Hematopoietic Agents
5. Others

Based on the drug type, the market has been segmented into monoclonal antibodies, immunomodulators, granulocyte-colony stimulating factor (G-CSF), hematopoietic agents and others.

Market Breakup by Cancer Type:

1. Lung Cancer
2. Colorectal Cancer
3. Cervical Cancer
4. Breast Cancer
5. Kidney Cancer
6. Stomach Cancer
7. Brain Cancer
8. Others

On the basis of the cancer type, the market has been segregated into the lung, colorectal, cervical, breast, kidney, stomach, brain and other forms of cancer.

Market Breakup by Distribution Channel:

1. Hospital Pharmacies
2. Online Pharmacies
3. Retail Pharmacies
4. Others

The market has been categorized based on the distribution channel into hospital pharmacies, online pharmacies, retail pharmacies and others.

Market Breakup by Region:

1. Europe
2. Asia Pacific
3. North America
4. Middle East and Africa
5. Latin America

Region-wise, the market has been classified into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., and F. Hoffmann-La Roche AG.

Browse More Reports By IMARC Group:

Hospital Acquired Disease Testing Market Research Report and Forecast: https://www.imarcgroup.com/hospital-acquired-disease-testing-market

Hepatitis Diagnostic Tests Market Research Report and Forecast: https://www.imarcgroup.com/hepatitis-diagnostic-tests-market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Information:
IMARC Services Pvt. Ltd.
Richard Lewis
Tel: 6317911145
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results